FORSKNINGSINFRASTRUKTUR - 12 FEBRUAR. Ketil F. Widerberg
|
|
|
- Madison Bridges
- 6 years ago
- Views:
Transcription
1 FORSKNINGSINFRASTRUKTUR - 12 FEBRUAR Ketil F. Widerberg
2 AGENDA Oslo Cancer Cluster Area of successful infrastructure Example immuno-oncology Area of potential Example precision medicine SIDE 2 DATO XX.XX.XXXX
3 OSLO CANCER CLUSTER COVERING THE ENTIRE VALUE CHAIN Oncology focused research and industry cluster dedicated to accelerate the development of new treatments and diagnostics 70 members covering the entire value chain: academic and clinical centers, start-ups and SMEs, international Pharma, TTOs, Biobanks and service providers Focus on collaboration, partnering and network building, innovation and capital development
4 OVER 80 YEARS DEDICATED TO CANCER Norwegian Radium Hospital 1932 Norwegian Cancer Registry 1952 Institute for Cancer Research 1953 Norwegian Radium Hospital Research Foundation 1986 Oslo Cancer Cluster 2006 NCE Status for Oslo Cancer Cluster 2007 Oslo Cancer Cluster Innovation Park & Oslo Cancer Cluster Incubator 2015
5 INFRASTRUCTURE TO SUPPORT GROWTH Radium Cancer Hospital Pathology /Digital Pathology Institute for Cancer Research National Cancer Registry Oslo Cancer Cluster Incubator Ullern High School
6 DESIGNED TO FIT THE SPECIALIZED NEEDS OF ONCOLOGY R&D AND BD
7 TRACK RECORD FOR SUCCESSFUL TRANSLATION FROM BECH TO BEDSIDE Discovery Preclinical Phase I Phase 2 Phase 3
8 OPPORTUNITY FOR VALUE CREATION ALGETA FROM $127M TO $2.9B IN 7 YEARS
9 IMMUNO - ONCOLOGY
10 NORWAY HAS LONG HISTORY IN CANCER IMMUNOTHERAPY RESEARCH Steinar Aamdal, Prof. MD, Ph.D. Head of Section Radium Hospital, OUS
11 AND IS IN FOREFRONT IN NEW CANCER IMMUNOTHERAPY RESEARCH Steinar Aamdal, Prof. MD, Ph.D. Head of Section Radium Hospital, OUS
12 NORWEGIAN IMMUNO-ONCOLOGY CONSORTIUM Scientific strength in oncology and immunology Several R&D projects and ongoing clinical trials (investigator & company initiated) Specific clinical trial competence & infrastructure Collaboration with international partners
13 IMMUNO ONCOLOGY INFRASTRUCTURE - IMPORTANT TO CREATE SUCCESSFULL COMPANIES Ultimovacs Dept. of Cellular Therapy Targovax
14 A UNIQUE BASE TO BUILD FUTURE COMPANIES ON Mario Sznol, MD,PhD, Yale Cancer Center; I was very impressed with both the very high level of clinical practice and the immunology science. I was somewhat envious of the clinical translational scientists in your group, particularly in immunology, and wish we had similar resources here Raj Parekh, General Partner, Advent Venture, London; I applaud what you are achieving in Oslo, very high quality science and medicine focused in oncology, which bodes well for the creation and growth of outstanding new Companies.
15 NORWAY A POTENTIAL TESTBED FOR CANCER PRECISION MEDICINE One health provider and lifetime individual ID numbers Little population mobility National clinical annotated biobanks Including National Genomics consortium Cancer register over 60 years All cancers registered by law Norway positioned to be a global testbed for personalized medicine
16 CANCER PRECISION MEDICINE A FIELD IN NEED OF INFRASTRUCTURE Register development Register development to enable prospective use, (e.g. data structure, improved biobanks ++) New equipment Physical infrastructure at hospitals and labs (e. g. sequensing ++) Information accessability Communication interfaces (e.g. industry, register, biobank, SLV etc) International infrastructure; International projects to address knowledge gaps (e.g. big data ++)
17 INTERNATIONAL INFRASTRUCTURE CANCER REGISTRY TEAMS UP WITH WORLD FASTEST COMPUTER?
18 DARE TO THINK BIG PUBLIC INFRASTRUCTURE CREATES THE FUTURE
19 PUBLIC INFRASTRUCTURE - TO DEVELOP NATIONAL COMPETETIVE ADVANTAGES
20 PUBLIC INFRASTRUCTURE DARE TO THINK BIG Public infrastructure developed Norway to the forefront in immuno oncology Norway has a unique position to be world leading in precision medicine Infrastructure should aim to strenghten national competetive advantages
Treatments of tomorrow: dementia research and drug discovery. Dr Matthew Norton Director of Policy and Strategy, Alzheimer s Research UK
Treatments of tomorrow: dementia research and drug discovery Dr Matthew Norton Director of Policy and Strategy, Alzheimer s Research UK More failure What is different about dementia drug discovery? The
Janus Serum Bank. Hilde Langseth MSc, PhD Senior Researcher and head of Janus Serum Bank Cancer Registry of Norway Department of Research
Janus Serum Bank Hilde Langseth MSc, PhD Senior Researcher and head of Janus Serum Bank Cancer Registry of Norway Department of Research Biobank Conference March 13th 2018 Felix konferansesenter, Oslo
Accelerating Translation at Dana-Farber Cancer Institute*
Accelerating Translation at Dana-Farber Cancer Institute* *and our partner institutions February 12, 2013 Edward J Benz JR, MD Dana Farber Cancer Institute 1 2 Academic Structure All Dana-Farber faculty
ITCC-P4 International Workshop
ITCC P4 GA No. 116064 ITCC-P4 International Workshop IMPROVING PEDIATRIC ONCOLOGY DRUG DEVELOPMENT THROUGH PRECLINICAL RESEARCH September 27 th and 28 th, 2018 // Amsterdam, NL By invitation The event
Bordeaux Integrated Oncology Research (BRIO) Part of the French National Cancer Institute (INCa) Integrated Research Sites Network (SIRICs)
Bordeaux Integrated Oncology Research (BRIO) Part of the French National Cancer Institute (INCa) Integrated Research Sites Network (SIRICs) 1 Labellised between 2011 & 2012 8 Integrated Cancer Research
economic impact of the roslin institute - Executive Summary Executive Summary by BiGGAR Economics
ECONOMIC IMPACT OF THE ROSLIN INSTITUTE Executive Summary by BiGGAR Economics 1 executive summary ECONOMIC IMPACT OF THE ROSLIN INSTITUTE 2011/12 293 staff 142 post-graduate students 25.4 million funding
Personalized medecine Biomarker
Patient Disease Diagnosis Risk prediction Personalized medecine Biomarker Targeted therapies Diagnostic Theranostic: Efficay Toxicity Treatment 1 THE CASE FOR PERSONALIZED MEDICINE IS COMPELLING.. Toxicity
What EU research policy can do for conditions such as chronic pain?
The EU Framework Programme for Research and Innovation HORIZON 2020 What EU research policy can do for conditions such as chronic pain? K Berkouk, PhD Deputy Head of Unit, Non-communicable diseases and
VISION» FOCUS DISCOVERY» CREATION
The Women s Health Research Institute at Northwestern University is turning possibility into reality. The possibility that we can improve women s health by requiring that all research studies put greater
The summit and its purpose
Sponsors: 1 The summit and its purpose The Translational Hearing Research Summit: Biological and Pharmacological Approaches was an international summit that gathered 159 delegates, from 14 countries to
Accelerate Your Research with Conversant Bio
Imagination has given us the steam engine, the telephone, the talkingmachine and the automobile, for these things had to be dreamed of before they became realities. So I believe that dreams... are likely
The 100,000 Genomes Project
The 100,000 Genomes Project Dr Matina Prapa, Scientific co ordinator Genomics England Clinical Interpretation Partnership William Harvey Research Institute Queen Mary University of London Genomics England
FinnGen as a Honey Jar for Additional Biomedical studies. Eero Punkka, Helsinki Biobank
1 FinnGen as a Honey Jar for Additional Biomedical studies 2 Eero Punkka, Helsinki Biobank FinnGen Step 1: Producing genome data 1O % of the population Step 2: Combining genome data with digital health
21 st Century Cures Initiative
STATEMENT OF THE AMERICAN ACADEMY OF ALLERGY, ASTHMA AND IMMUNOLOGY TO THE HOUSE COMMITTEE ON ENERGY AND COMMERCE on the 21 st Century Cures Initiative June 13, 2014 The American Academy of Allergy, Asthma
Agenda 2030: One Nation Labour s Plan for science Response from Alzheimer s Research UK
Agenda 2030: One Nation Labour s Plan for science Response from Alzheimer s Research UK 1. Introduction 1.1. Alzheimer s Research UK is the UK s leading dementia research charity. As research experts,
Combining HS-110 and anti-pd-1 in NSCLC. September 1, 2015
Combining HS-110 and anti-pd-1 in NSCLC September 1, 2015 Forward Looking Statements This presentation includes statements that are, or may be deemed, forward-looking statements. In some cases, these forward-looking
The Value of Product Development Partnerships in Vaccine Innovation. Hansi J. Dean International AIDS Vaccine Initiative
The Value of Product Development Partnerships in Vaccine Innovation Hansi J. Dean International AIDS Vaccine Initiative The Product Development Partnership Model A non-profit partnership of public and
REPORT TO CONGRESS Multi-Disciplinary Brain Research and Data Sharing Efforts September 2013 The estimated cost of report or study for the Department of Defense is approximately $2,540 for the 2013 Fiscal
2017 Strategic Plan. Icahn School of Medicine at Mount Sinai. Dennis S. Charney, MD
Icahn School of Medicine at Mount Sinai 2017 Strategic Plan Dennis S. Charney, MD Strategic Plan 2006 A Success Story How Did We Achieve Success? 1. Established world-class interdepartmental, multi-disciplinary
NCI Cancer Moonshot. Christine Siemon National Cancer Institute, NIH. November 30, 2017
NCI Cancer Moonshot Christine Siemon National Cancer Institute, NIH November 30, 2017 Presidential Memo 2016 Overall Goals of the Cancer Moonshot Accelerate progress in cancer, including prevention & screening
DZNE & BfArM Collaboration and future challenges
DZNE & BfArM Collaboration and future challenges Prof. Pierluigi Nicotera, MD PhD DZNE Facts on Dementia & other Neurodegenerative Diseases Estimated total funding on dementia research in Germany: i.e.
NIHR Supporting collaboration in life sciences research
NIHR Supporting collaboration in life sciences research Dr Matt Hallsworth - Head of External Relations, NIHR Office for Clinical Research Infrastructure (NOCRI) Research funders build capabilities and
NOTE TO THE FACULTY BOARD
NOTE TO THE FACULTY BOARD To: Faculty of Medicine From: Centre for Global Health Attachments: 3 Date of meeting: 8.5.18 Case title: Consolidated plan for the Centre for Global Health (CGH) Purpose / Why
Master of Science in Management: Fall 2018 and Spring 2019
Master of Science in Management: Fall 2018 and Spring 2019 2 - Required Professional Development & Career Workshops MGMT 7770 Prof. Development Workshop 1/Career Workshops (Fall) Wed. 9am, 12pm & 3pm MGMT
The Cancer Moonshot ECCO2018 September 7, 2018
The Cancer Moonshot ECCO2018 September 7, 2018 Dinah S. Singer, Ph.D. Deputy Director National Cancer Institute, NIH www.cancer.gov/moonshot Goals of the Cancer Moonshot Accelerate progress in cancer,
ACCELERATING PROGRESS THROUGH COLLABORATION ACCELERATOR AWARD CASE STUDIES
ACCELERATING PROGRESS THROUGH COLLABORATION ACCELERATOR AWARD CASE STUDIES CRUK CENTRES NETWORK At Cancer Research UK we recognise the crucial role that infrastructure plays in creating a dynamic and responsive
In Cancer s Genes. Pauline Helle, Co-President of Think Pink McGill
In Cancer s Genes Pauline Helle, Co-President of Think Pink McGill Recent and even controversial findings give an astonishing glimpse into the future of research, prevention and potential cure for breast
AACR JOURNAL PORTFOLIO MUST-HAVE CONTENT ANYTIME, ANYWHERE
AACR JOURNAL PORTFOLIO MUST-HAVE CONTENT ANYTIME, ANYWHERE 2016 American Association for Cancer Research WHO WE ARE Founded in 1907 Oldest and largest scientific organization focused on cancer research
R e s e a r c h S t r a t e g y
Sheffield Teaching Hospitals NHS Foundation Trust Academic Directorate of Specialised Cancer R e s e a r c h S t r a t e g y Academic Directorate of Specialised Cancer Research Strategy Executive Summary
BORDET DEPARTMENT RADIATION ONCOLOGY
BORDET DEPARTMENT RADIATION ONCOLOGY The Radiation Oncology Department has been providing patients with high quality, tailored radiation oncology care for the last 60 years in a multidisciplinary setting
Translating Duke Health. Accelerating discovery and its translation
Translating Duke Health Accelerating discovery and its translation Translating Duke Health Biomedical discovery is accelerating innovative and revolutionary advancements in our understanding of human biology,
Alcohol Research UK Research Strategy
Alcohol Research UK Research Strategy 2015-18 Supporting research to reduce alcohol-related harm www.alcoholresearchuk.org Alcohol Research UK Research Strategy 2015-18 Foreword Professor Alan-Maryon Davies
NIH Alzheimer s Disease Centers Panel Recommendations
NIH Alzheimer s Disease Centers Panel Recommendations In June, 2017 NIA engaged leading experts from academia, industry and non-profit foundations, working in Alzheimer s and other complex diseases, in
JOSLIN INGENUITY DIGITAL IMPACT INNOVATION BIG DATA CAPACITY TRANSLATIONAL AGILITY COLLABORATION COLLABORATION JENESIS
CONFIDENCE OUTCOMES ALLIANCES CATALYST COLLABORATION AGILITY JOSLIN INGENUITY CAPACITY IMPACT INNOVATION GLOBAL ACCELERATION COLLABORATION JENESIS BIG DATA TRANSLATIONAL DIGITAL Contents 2 Partnering for
National Academies Next Generation SAMPLE Researchers TITLE Initiative HERE
National Academies Next Generation SAMPLE Researchers TITLE Initiative HERE Dennis A. Dean, II, PhD Sanofi Auditorium July 13, 2017 sevenbridges.com A little about me Research Experience Analytics and
PRESS RELEASE FOR IMMEDIATE RELEASE SINGAPORE INSTITUTES COLLABORATE WITH SAMSUNG MEDICAL CENTER TO IMPROVE TREATMENT OF LIVER CANCER
PRESS RELEASE FOR IMMEDIATE RELEASE SINGAPORE INSTITUTES COLLABORATE WITH SAMSUNG MEDICAL CENTER TO IMPROVE TREATMENT OF LIVER CANCER This collaboration creates the world s first clinically reliable and
BUILDING AN INFORMATION PLATFORM FOR CANCER RESEARCH & EVIDENCE-BASED HEALTHCARE
BUILDING AN INFORMATION PLATFORM FOR CANCER RESEARCH & EVIDENCE-BASED HEALTHCARE William S. Dalton, PhD, MD CEO, M2Gen & Director, Personalized Medicine Institute, Moffitt Cancer Center JULY 17, 2013 MOFFITT
C A N C É R O P Ô L E L Y O N A U V E R G N E R H Ô N E - A L P E S
Cancer Research Cluster to Facilitate and Structure Oncology Research C A N C É R O P Ô L E L Y O N A U V E R G N E R H Ô N E - A L P E S s P E E D I N G U P P R O G R E S S CANCÉROPÔLE LYON AUVERGNE RHÔNE-ALPES
IMI2 T1DM Call Topic Text: Translational approaches to disease modifying therapy of T1DM
IMI2 T1DM Call Topic Text: Translational approaches to disease modifying therapy of T1DM Dr Anke M Schulte, Head of Islet Biology Department Sanofi-Diabetes Frankfurt, Germany 11th of July, 2014 General
John Parrish-Sprowl Co-Director Global Health Communication Center IU School of Liberal Arts
John Parrish-Sprowl Co-Director Global Health Communication Center IU School of Liberal Arts My Background On the board of 5 nonprofit organizations and president of 2 Involved in various capacity building
Championing patients every step of the way
Championing patients every step of the way The majority of people living with a rare disease have no treatment for their condition. At Shire, we have long believed we have a unique opportunity to champion
PROJECT TRICALS AN INTERNATIONAL COLLABORATION TO FIND EFFECTIVE TREATMENTS FOR AMYOTROPHIC LATERAL SCLEROSIS
PROJECT TRICALS AN INTERNATIONAL COLLABORATION TO FIND EFFECTIVE TREATMENTS FOR AMYOTROPHIC LATERAL SCLEROSIS BACKGROUND Amyotrophic Lateral Sclerosis (ALS), also known as Motor Neurone Disease (MND) is
TPMI Presents: Translational Genomics Research Update, Opportunities and Challenges
TPMI Presents: Translational Genomics Research Update, Opportunities and Challenges April 12, 2016 Darren D. O Rielly, Ph.D., FCCMG Director, Molecular Genetics Laboratory, Eastern Health Director, Translational
Translational Research in Oncology in the Era of Personalized Medicine and Open Science: Are the Current Funding Mechanisms Fit for Purpose?
Policy Brief Draft- Funding mechanisms: a case study on Translational Oncology Julio E. Celis Member of RISE Dainius Pavalkis Member of RISE This document has been prepared for the European Commission
Association of American Cancer Institutes
Association of American Cancer Institutes Statement by the Association of American Cancer Institutes on Fiscal Year (FY) 2016 Appropriations for the Department of Health and Human Services Subcommittee
Industry Partners. Information and Benefits
Industry Partners Information and Benefits 1968 to today Founded in 1968, the EACR is Europe s professional membership association for those working and studying in cancer research, with over 10,000 members
Break-out session: Nordic Collaboration within Biobank Sciences
1 Break-out session: Nordic Collaboration within Biobank Sciences Kristian Hveem, MD, PhD, Professor in clinical epidemiology, NTNU Leader HUNT Biobank and Biobank Norway/BBMRI.se Leader Nordic Biobank
The future of cancer care... now 1. Strategic Plan
2017 2021 The future of cancer care... now 1 Strategic Plan 2 Duke Cancer Institute 2017 2021 Strategic Plan Mission: We discover, develop and deliver the future of cancer care... now. Vision: At Duke
BASIS SLIDE DECK. Bimetra Biobank: Evaluation of sustainability at 5th year anniversary. Prof. Dr. Ir. Sofie Bekaert Head of Department Bimetra
Bimetra Biobank: Evaluation of sustainability at 5th year anniversary Prof. Dr. Ir. Sofie Bekaert Head of Department Bimetra BASIS SLIDE DECK President Board of directors BBMRI.be Councilor ESBB Liaison
NCRI Biomarkers & Imaging CSG Cell-free DNA workshop
NCRI Biomarkers & Imaging CSG Cell-free DNA workshop Workshop Report Christie Education Centre, Manchester 30th January 2014 Sponsored by Workshop summary 86 delegates from a variety of specialities attended
The Norwegian PSC Research Center Biobank
The Norwegian PSC Research Center Biobank Trine Folseraas Norwegian PSC Research Center, Department of Transplantation Medicine, Division of Surgery, Inflammatory Medicine and Transplantation, Oslo University
Pfizer Support to European and International Patient Organisations based in Belgium & Luxembourg in 2016
Pfizer Support to European and International Patient Organisations based in Belgium & Luxembourg in 2016 Please note that all information in this document is also disclosed in the overall report on Pfizer
Partnering in Oncology Sharing a Vision to Help Prolong and Improve Patients Lives. Oncology Therapeutic Area Janssen Research & Development, LLC
Partnering in Oncology Sharing a Vision to Help Prolong and Improve Patients Lives Oncology Therapeutic Area Janssen Research & Development, LLC The patients are waiting. Dr. Paul Janssen To Our Potential
London Medical Imaging & Artificial Intelligence Centre for Value-Based Healthcare. Professor Reza Razavi Centre Director
London Medical Imaging & Artificial Intelligence Centre for Value-Based Healthcare Professor Reza Razavi Centre Director The traditional healthcare business model is changing Fee-for-service Fee-for-outcome
Neurofibromatosis (NF) Center
Washington University Neurofibromatosis (NF) Center THE NF CENTER: EXCEPTIONAL CARE THROUGH GROUNDBREAKING RESEARCH An international leader in research and treatment of neurofibromatosis (NF), the Washington
TREAT-NMD and the Role of the Industry in Orphan Diseases. Dr. Stefanie Possekel Santhera Pharmaceuticals
TREAT-NMD and the Role of the Industry in Orphan Diseases Dr. Stefanie Possekel Santhera Pharmaceuticals TREAT-NMD EU-funded infrastructure to accelerate therapy development in neuromuscular diseases Clinical
THE CANADA-ISRAEL TRANS-ATLANTIC COLLABORATION FOR BRAIN STUDIES
DISCUSSION PAPER THE CANADA-ISRAEL TRANS-ATLANTIC COLLABORATION FOR BRAIN STUDIES A Collaborative Research Partnership between Dalhousie University and Ben-Gurion University of the Negev WHERE BREAKTHROUGHS
Defeat Dementia. Five years and 100m of investment to power transformational patient benefit
Defeat Dementia Five years and 100m of investment to power transformational patient benefit An ambition to solve our greatest medical challenge Dementia is our greatest medical challenge. There is currently
Identification & Diagnosis of Cryptogenic Stroke What is NINDS/role
Identification & Diagnosis of Cryptogenic Stroke What is NINDS/role October 9, 2015 Scott Janis, Ph.D. Program Director, National Institute of Neurological Disorders and Stroke, The National Institute
AURIA BIOBANK. Turning Hospital Biobank Data into Real-World Evidence using Artificial Intelligence Tools
AURIA BIOBANK Turning Hospital Biobank Data into Real-World Evidence using Artificial Intelligence Tools Samu Kurki, PhD, Senior Data Scientist, Auria Biobank, Turku University Hospital, University of
Introduction to Wessex AHSN Cathy Rule Project Manager Alcohol Quality Improvement Programme. 25 th June 2014
Introduction to Wessex AHSN Cathy Rule Project Manager Alcohol Quality Improvement Programme 25 th June 2014 Our vision To bring discovery and innovation into the Wessex health system so that the population
HAT DNDi program progress and evolution in the path to elimination. Dr Antoine Tarral. HAT Platform, Kampala October 2018
HAT DNDi program progress and evolution in the path to elimination Dr Antoine Tarral HAT Platform, Kampala October 2018 DNDi s Mission To develop new drugs or new formulations of existing drugs for people
EDUCATIONAL SEMINAR. Humanized Mouse Models in Pre- Clinical Efficacy Studies in Oncology. BIOCOM CRO Event January 23, 2018
EDUCATIONAL SEMINAR Humanized Mouse Models in Pre- Clinical Efficacy Studies in Oncology BIOCOM CRO Event January 23, 2018 Agenda 8.00 8.30 Registration and networking 8.30 8.45 Introduction, by Jussi
UC HEALTH RESEARCH INSTITUTE STRATEGIC PLAN
UC HEALTH RESEARCH INSTITUTE STRATEGIC PLAN 2016-2020 1 2 OUR VISION Excellence in research is at the core of our vision for UC-Health Research Institute (HRI) which brings together critical mass in biomedicine,
AUSTRALIA S FIRST DEDICATED DEPARTMENT OF DIABETES. med.monash.edu/cecs/diabetes
AUSTRALIA S FIRST DEDICATED DEPARTMENT OF DIABETES med.monash.edu/cecs/diabetes 2 MONASH UNIVERSITY DEPARTMENT OF DIABETES AT A GLANCE FAST FACTS WHO WE ARE Monash University s Department of Diabetes is
Master of Business Administration: Fall 2018/Spring 2019/Fall Semesters (45 Credits)
Master of Business Administration: Fall 2018/Spring 2019/Fall 2019-3 Semesters (45 Credits) 3 Required non-credit courses: MGMT 7230 Professional Development Workshop I (Fall) - Wednesday 2-3:50pm MGMT
POSITION DESCRIPTION. Employment Status: Maternity Leave Contract 5 months (Jan-May 2018) PURPOSE OF POSITION DESCRIPTION
POSITION DESCRIPTION Position Title: Location: Research Coordinator Clinical Trials National Secretariat, Brisbane-based Employment Status: Maternity Leave Contract 5 months (Jan-May 2018) Reporting Relationships:
BIOBANKS THE ONLY BANKS WHERE YOUR DEPOSITS ARE PRICELESS
BIOBANKS THE ONLY BANKS WHERE YOUR DEPOSITS ARE PRICELESS Eva Ortega-Paíno, PhD Research and Biobank Coordinator BIS (Biobank in Sweden)-Lund University and Region Skåne Biobank BD47 (Laboratory Medicine)
New Horizons for Vaccine R&D&I in Europe
New Horizons for Vaccine R&D&I in Europe Health, Demographic Change and Wellbeing Ruxandra Draghia-Akli MD, PhD Directorate E - Health Research DG - Research & Innovation European Commission Why EU support
Melanoma Research Alliance-Pfizer Academic-Industry Partnership Awards
Melanoma Research Alliance-Pfizer Academic-Industry Partnership Awards Wendy K.D. Selig, President & CEO, MRA Julia Perkins, M.D. Medical Director, Oncology, Pfizer Melanoma Research Alliance Mission:
BRANCHED-CHAIN AMINO ACIDS FOUND TO REGULATE THE DEVELOPMENT AND PROGRESSION OF CANCER
SCIENTIFIC ADVISORY BRANCHED-CHAIN AMINO ACIDS FOUND TO REGULATE THE DEVELOPMENT AND PROGRESSION OF CANCER Researchers from A*STAR s SBIC have discovered how changes in BCAA metabolism influence the development
Bayer to Present New Data on Advancing Oncology Portfolio. New Preclinical and Early Clinical Data Evaluating Innovative Compounds in Drug Development
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com 105 th Annual Meeting American Association for Cancer Research Bayer to Present
Watson Summit Prague 2017
Watson for Oncology Matěj Adam Watson Health Executive May 2017 Watson Summit Prague 2017 an IBM Company Leadership & 23 Years Patent Leadership Research Spend Global Presence Technology 7300+ 2015 $6B
CANCER DRUG DEVELOPMENT
FACILITATING SUCCESSFUL CANCER DRUG DEVELOPMENT TURNING TRIALS INTO THERAPY TRIAL ACCELERATION SERVICES: Physician-Focused Patient Recruitment TRANSLATING INNOVATION INTO PATIENT CARE CLINICAL APPLICATION
Development of novel inhaled antibiotic regimens in patients with cystic fibrosis (CF) and patients with non-cf bronchiectasis (BE)
Development of novel inhaled antibiotic regimens in patients with cystic fibrosis (CF) and patients with non-cf bronchiectasis (BE) Dr. Juliane Bernholz, Novartis (Coordinator) Dr. Andrea Appenzeller,
Murtha Cancer Center The DoD Cancer Center of Excellence
Accelerating Progress against Cancer through Collaboration Center of Excellence Oversight Board September 10, 2013 Colonel Craig D. Shriver, MC, USA. FACS Director 1 Summary Murtha Cancer Center Overview
SAVING LIVES: ACHIEVING MORE
SAVING LIVES: ACHIEVING MORE ANTHONY NOLAN ORGANISATIONAL STRATEGY FOR 2015-2018 WHERE WE RE COMING FROM In 1974, we were the world s first stem cell donor register. And over 40 years later, we re at the
62 accc-cancer.org May June 2016 OI
62 accc-cancer.org May June 2016 OI BY MICHAEL A. CALIGIURI, MD; WILLIAM S. DALTON, PHD, MD; LORNA RODRIGUEZ, MD, PHD; THOMAS SELLERS, PHD, MPH; AND CHERYL L. WILLMAN, MD Reshaping Cancer Research & Treatment
Prof. Anne McKinney D.Phil Associate Vice-Principal, Research & Innovation (Health Affairs) McGill University.
Prof. Anne McKinney D.Phil Associate Vice-Principal, Research & Innovation (Health Affairs) McGill University Email: anne.mckinney@mcgill.ca The HBHL Initiative $84 million over seven years from the Canada
a case to support THE HEART & VASCULAR CENTER
a case to support THE HEART & VASCULAR CENTER facing TODAY S CHALLENGES Despite remarkable progress in prevention and treatment, cardiovascular diseases including heart attack, stroke, and peripheral vascular
OHSU Knight Cancer Institute Overview and Update
OHSU Knight Cancer Institute Overview and Update for Senate Health Care and Human Services Committee Steve Stadum, COO, OHSU Knight Cancer Institute September 15, 2014 Presentation Brief Overview of OHSU
UNRAVELING THE MYSTERY BEHIND HIV/AIDS
PRESS RELEASE 3 MAR 2010 UNRAVELING THE MYSTERY BEHIND HIV/AIDS New findings by Nobel Laureate shed light on the elusive AIDS virus and may lead to effective HIV vaccine development 1. Professor Francoise
Scientific Discoveries Allow Development of Targeted Therapeutics for Individuals with Autism Spectrum Disorders
Scientific Discoveries Allow Development of Targeted Therapeutics for Individuals with Autism Spectrum Disorders Randall L. Carpenter, M.D. Co-Founder, President and CEO August 9, 2012 Research Supported
I, Mary M. Langman, Director, Information Issues and Policy, Medical Library Association
I, Mary M. Langman, Director, Information Issues and Policy, Medical Library Association (MLA), submit this statement on behalf of MLA and the Association of Academic Health Sciences Libraries (AAHSL).
CPRIT Overview. Cancer Centers Administrators Forum April 4, 2016
CPRIT Overview Cancer Centers Administrators Forum April 4, 2016 CPRIT s Unique Role in the Fight Against Cancer Overview: Created by the Texas Legislature and citizens in 2007 $3 billion over 10 years
Parkinson s Research and the New Centre for Brain Health at UBC. Case for Support The University of British Columbia Faculty of Medicine
Parkinson s Research and the New Centre for Brain Health at UBC Case for Support The University of British Columbia Faculty of Medicine THE VALUE OF A HEALTHY BRAIN By 2020, brain disease will overtake
EC research and innovation strategy and actions
EC research and innovation strategy and actions for preparedness and response to outbreaks IMI Stakeholder Forum 28-29 September 2016 Line Matthiessen Head of Unit E.3 Health Directorate DG Research &
Company overview. Highlights for the 1 st quarter 2018 (January-March)
Company overview Vaccibody is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies. The company is a leader in the rapidly developing field of
2018 INFUSE CALL FOR INNOVATION
2018 INFUSE CALL FOR INNOVATION Leveraging digital technologies for registration, identification, digital record-keeping and follow-up to ensure healthier futures Imagine a future in which all children
R&D Status in Romania
R&D Status in Romania Romania Economy is the second largest country in the Central and Eastern Europe (after Poland); it has a population of 22 million people; it benefits from a strategic geographic position;
Master of Science in Management: Fall 2017 and Spring 2018
Master of Science in Management: Fall 2017 and Spring 2018 2 - Required Professional Development & Career Workshops MGMT 7770 Prof. Development Workshop 1/Career Workshops (Fall) Wed. 9am, 12pm & 3pm MGMT
FOSTERING THE NEXT GENERATION OF RESEARCHER IN HEALTH DISPARITIES!
FOSTERING THE NEXT GENERATION OF RESEARCHER IN HEALTH DISPARITIES! Translational Research at the Puerto Rico clinical and Translational Consortium. Defining Translational Research Series Objective. 1.
Parkinson s Institute and Clinical Center Appoints Anthony Santiago, M.D., Neurologist and Movement Disorders Specialist as Chief Medical Officer
Press Release For Immediate Release October 30, 2017 Contact: Chris Di Salvo Mobile: (408) 506-0455 E-mail: profeff@aol.com Parkinson s Institute and Clinical Center Appoints Anthony Santiago, M.D., Neurologist
RECENT TRENDS. The Impact of the NCI and NIBIB
The Impact of the NCI and NIBIB James Deye, Ph.D. Program Director on Medical Physics RECENT TRENDS doubling of the NIH budget over last 5 years; appointment of new heads of NIH and NCI; creation of NIBIB;
Cancer Progress. The State of Play in Immuno-Oncology
Cancer Progress The State of Play in Immuno-Oncology Axel Hoos, MD, PhD VP, Oncology R&D, Glaxo Smith Kline Co-Director, Cancer Immunotherapy Consortium Key Drivers in Immuno-Oncology Science Methods Combinations
Vaccines and Immunization research & development
32 nd International conference on Vaccines and Immunization research & development 0 http://vaccines.global-summit.com/america/ Invitation Dear Attendees, We are glad to announce the 32 nd International
BBMRI-ERIC and BBMRI.fi
BBMRI-ERIC and BBMRI.fi Connecting Biobanks at the European and National level to proviede hiqh quality samples and associated data for health 29.05.2018 Anu Jalanko Terveystalo Biobank Finland 31/05/2018
Practice and challenges in Assuring the Quality of Breast Cancer Care in Europe - Norway
Practice and challenges in Assuring the Quality of Breast Cancer Care in Europe - Norway Solveig Hofvind Head of the Norwegian Breast Cancer Screening Program Baveno, Lago Maggiore, Italy Dec 10, 2015
Radiation Therapy in Africa
Radiation Therapy in Africa Surbhi Grover, MD MPH Senior Lecturer, School of Medicine, University of Botswana Oncology Consultant, Princess Marina Hospital, Botswana Assistant Professor, Dept of Radiation